High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood, Hussein A. Tawbi
Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 74; DOI: 10.1186/s40425-017-0279-5